This announcement is a separate document:
诺诚健华医药有限公司自愿披露关于ICP-332在美国完成首例受试者给药的公告
Innocare Pharmaceutical voluntarily discloses the announcement of the first dosing of ICP-332 trial subjects in the United States.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.